03 November 1997
Long-term effects of vaccination against hepatitis virus B infection in children with neoplastic disease
Jan Styczyński, Mariusz Wysocki, Sylwia Kołtan, Andrzej Kurylak, Anna Balcar-BorońMed Sci Monit 1997; 3(6): CR864-868 :: ID: 501816
Abstract
The purpose of the study was to assess the durability of humoral immunity in children with neoplastic disease 2.5 years after vaccination against hepatitis B virus. The study included 53 children divided into 3 groups, according to the method of passive-active prophylaxis. In group A first came passive prophylaxis during intensive chemotherapy, followed by the vaccination during supportive treatment; in group B children were vaccinated from the very beginning of chemotherapy with simultaneous administration of 2 doses of anti-HBs immunoglobulin; in group C patients received vaccination only after the completion of chemotherapy. Engerix-B vaccine was used for vaccination, and was administered in double doses, in regimen 0-1-2-8 months. Humoral response was evaluated in the 6th and 30th month following the fourth vaccination. After the vaccination cycle was completed, seroprotection was obtained in 66.7% of children in group A, 81.3% in group B and 100% in group C. Two and a half years after the termination of vaccination, all patients with primary seroconversion still possessed anti-HBs antibodies, while in two children the anti-HBs antibodies appeared after the discontinuation of chemotherapy. Anti-HBs antibody level increased in 45.3% of patients. Among patients who received the last dose of vaccine upon the completion of chemotherapy, as compared to those who received the last dose of vaccine during chemotherapy, we found a higher percentage of seroconversion to anti-HBs³10 IU/l (p<0.01) and higher mean arithmetic (p<0.05) in the 30th month after completion of vaccination. Geometric mean value of protective level of antibodies was in these patients more than two times higher. Long-term effects of vaccination in children with neoplastic disease reveal improvement of humoral response after the discontinuation of chemotherapy. More permanent results were obtained in children who received the last dose of the vaccine upon the completion of treatment.
Keywords: HBV infection, Vaccination, antibodies maintenance, children neoplasm
540 1
Editorial
01 June 2023 : Editorial
Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic PreparednessDOI: 10.12659/MSM.941209
Med Sci Monit 2023; 29:e941209
In Press
07 Jun 2023 : Review article
Ultrasound-Guided Brachial Plexus Block by Costoclavicular Space Approach: A Narrative ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.939920
05 Jun 2023 : Clinical Research
Comparison of Texture and Color Enhancement Imaging with White Light Imaging in 52 Patients with Short-Segm...Med Sci Monit In Press; DOI: 10.12659/MSM.940249
05 Jun 2023 : Laboratory Research
Comparison of Composite Resin (Duo-Shade) Shade Guide with Vita Ceramic Shades Before and After Chemical an...Med Sci Monit In Press; DOI: 10.12659/MSM.940949
02 Jun 2023 : Database Analysis
The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952